HDAC9 and Miyoshi myopathy: Despite the improvement of MM patient survival through the development of novel agents, including new generation of IMiDs or proteasome inhibitors, monoclonal antibodies and HDAC inhibitors, the acquisition of drug resistance is the major limitation of MM therapy.